Effect of organ culture on the survival of thyroid allografts in mice

Transplantation
K J LaffertyD W Talmage

Abstract

Mouse thyroid can be maintained in organ culture for 4 weeks. Uncultured BALB/c thyroid is rejected 10-15 days after transplantation under the kidney capsule of H-2 disparate recipients (C57BL, CBA). Organ culture of thyroid tissue prior to transplantation prolongs allograft survival. This prolongation of graft survival increases with increasing time in culture and 80-90% of BALB/c thyroids maintained in culture for 26 days survive in allogeneic CBA recipients for a 60- to 70-day test period. These allografts show normal function as measured by 125I uptake, and show no histological evidence of chronic rejection. Cultured allografts can be rejected if the host's immune system is stimulated with viable leukocytes of donor origin. Host animals carrying a functioning allograft are not tolerant of donor tissues and will reject a second uncultured allograft from the same donor strain.

Citations

Jun 1, 1993·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·T E StarzlJ J Fung
Jan 1, 1986·Archives of Dermatological Research·J ThivoletG Mauduit
Nov 1, 1988·Biulleten' eksperimental'noĭ biologii i meditsiny·V N BlomkinIu V Kiprenskiĭ
Jun 1, 1986·World Journal of Surgery·D W Gray, P J Morris
Jan 1, 2010·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Elizabeth Ingulli
Mar 1, 1983·Survey of Ophthalmology·L S Braude, J W Chandler
May 1, 1993·Trends in Pharmacological Sciences·H Waldmann, S Cobbold
Jun 1, 1993·Immunology Today·H Waldmann, S Cobbold
Aug 2, 1980·Lancet·S D Somerfield
Mar 31, 1999·Immunology Today·D S Gould, H Auchincloss
Feb 1, 1997·Human Immunology·K J Lafferty, L S Gazda
Nov 5, 1999·Nature Medicine·H Waldmann
Aug 1, 1987·Immunology and Cell Biology·L K Ashman
Oct 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·D W TalmageK J Lafferty
Jan 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·W K SilversC F Barker
Mar 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·D H VesoleD W Talmage
Apr 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M A ReesA Singer
Jan 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·Y WangK J Lafferty
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·H AuchinclossL H Glimcher
Feb 1, 1984·The Journal of Experimental Medicine·L AndrusE Reich
Sep 1, 1984·The Journal of Experimental Medicine·A Granelli-PipernoE Reich
Sep 15, 2004·Tissue Engineering·M GriffithsH Navsaria
Jan 1, 1997·Journal of Viral Hepatitis·R Lechler, F M Marelli-Berg
Jan 1, 1977·Scandinavian Journal of Immunology·A J Cunningham, K J Lafferty
Jan 1, 1977·Immunological Reviews·K J Lafferty, J Woolnough
Jan 1, 1977·Immunological Reviews·W F Davidson
Jan 13, 2000·Immunological Reviews·F M Marelli-Berg, R I Lechler
Oct 1, 2011·Evidence-based Complementary and Alternative Medicine : ECAM·Azamjon B SolievKeiichi Enomoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.